Laura Moncada
Family · Melbourne, FLNPI 1942711361
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $856, more than ten times the $12 reported in 2021.
Across 129 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$447
- AbbVie$426
- Lilly USA, LLC$306
- Amgen$188
- GSK$149
- Boehringer Ingelheim$115
- plus $780 from 20 others
What the payments were for
- Food & beverage$2,412100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $447 |
| AbbVie | 19 | $426 |
| Lilly USA, LLC | 15 | $306 |
| Amgen | 11 | $188 |
| GSK | 7 | $149 |
| Boehringer Ingelheim | 6 | $115 |
| Exact Sciences | 5 | $107 |
| Phathom Pharmaceuticals, Inc. | 1 | $82 |
| AstraZeneca | 3 | $75 |
| Abbott | 3 | $63 |
| Novartis | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| Bayer | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Harmony Biosciences LLC | 1 | $41 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Medtronic | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$108
How this compares
$2,412 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 110 | $87,146 |
| OzempicSemaglutide | 40 | $47,468 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $12,681 |
| Baclofen | 107 | $1,177 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $524 |
| Levothyroxine Sodium | 75 | $506 |
| Rosuvastatin Calcium | 50 | $502 |
| Omeprazole | 28 | $497 |
| Diclofenac Sodium | 19 | $484 |
| Bupropion XlBupropion Hcl | 35 | $469 |
| Methylprednisolone | 49 | $420 |
| Losartan Potassium | 91 | $411 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 44 | $400 |
| Gabapentin | 36 | $347 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $115 | $87,146110 claims |
| Novo NordiskOzempic | $447 | $47,46840 claims |
| GSKTrelegy Ellipta | $149 | $12,68113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Melbourne
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.